These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 16792983)

  • 1. [Cyclooxygenase-2: a new therapeutic target in atherosclerosis?].
    Páramo JA; Beloqui O; Orbe J
    Med Clin (Barc); 2006 May; 126(20):782-6. PubMed ID: 16792983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monocyte cyclooxygenase-2 activity: a new therapeutic target for atherosclerosis?
    Páramo JA; Rodríguez JA; Beloqui O; Orbe J
    Curr Drug Targets Cardiovasc Haematol Disord; 2005 Aug; 5(4):303-11. PubMed ID: 16101563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [What is new about nonsteroidal antiinflamatory drugs?].
    Dzielska-Olczak M
    Pol Merkur Lekarski; 2007 Dec; 23(138):454-8. PubMed ID: 18432131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The future of traditional nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors in the treatment of inflammation and pain.
    Sciulli MG; Capone ML; Tacconelli S; Patrignani P
    Pharmacol Rep; 2005; 57 Suppl():66-85. PubMed ID: 16415488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular complications of non-steroidal anti-inflammatory drugs.
    Fosslien E
    Ann Clin Lab Sci; 2005; 35(4):347-85. PubMed ID: 16254252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysis.
    Gunter BR; Butler KA; Wallace RL; Smith SM; Harirforoosh S
    J Clin Pharm Ther; 2017 Feb; 42(1):27-38. PubMed ID: 28019014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms underlying the cardiovascular effects of COX-inhibition: benefits and risks.
    Martínez-González J; Badimon L
    Curr Pharm Des; 2007; 13(22):2215-27. PubMed ID: 17691994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An evidence-based evaluation of the gastrointestinal safety of coxibs.
    Bombardier C
    Am J Cardiol; 2002 Mar; 89(6A):3D-9D. PubMed ID: 11909555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclooxygenase-2 Inhibitors as a Therapeutic Target in Inflammatory Diseases.
    Ferrer MD; Busquets-Cortés C; Capó X; Tejada S; Tur JA; Pons A; Sureda A
    Curr Med Chem; 2019; 26(18):3225-3241. PubMed ID: 29756563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclooxygenase isoforms and atherosclerosis.
    Belton O; Fitzgerald DJ
    Expert Rev Mol Med; 2003 Mar; 5(9):1-18. PubMed ID: 14987412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclooxygenase-2 inhibitors: what went wrong?
    James MJ; Cleland LG
    Curr Opin Clin Nutr Metab Care; 2006 Mar; 9(2):89-94. PubMed ID: 16477171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The select cyclooxygenase-2 inhibitor celecoxib reduced the extent of atherosclerosis in apo E-/- mice.
    Jacob S; Laury-Kleintop L; Lanza-Jacoby S
    J Surg Res; 2008 May; 146(1):135-42. PubMed ID: 17950326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Celecoxib for the treatment of atherosclerosis.
    Papageorgiou N; Zacharia E; Briasoulis A; Charakida M; Tousoulis D
    Expert Opin Investig Drugs; 2016; 25(5):619-33. PubMed ID: 26940257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
    Valat JP; Deray G; Héloire F
    Presse Med; 2006 Sep; 35 Suppl 1():25-34. PubMed ID: 17870550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk.
    Solomon DH; Avorn J; Stürmer T; Glynn RJ; Mogun H; Schneeweiss S
    Arthritis Rheum; 2006 May; 54(5):1378-89. PubMed ID: 16645966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COX-2-dependent and independent effects of COX-2 inhibitors and NSAIDs on proatherogenic changes in human monocytes/macrophages.
    Voloshyna I; Kasselman LJ; Carsons SE; Littlefield MJ; Gomolin IH; De Leon J; Reiss AB
    J Investig Med; 2017 Mar; 65(3):694-704. PubMed ID: 27940550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Selective inhibitors of cyclooxygenase-2 (COX-2), celecoxib and parecoxib: a systematic review].
    Mateos JL
    Drugs Today (Barc); 2010 Feb; 46 Suppl A():1-25. PubMed ID: 20224826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cardiovascular pharmacology of COX-2 inhibition.
    Fries S; Grosser T
    Hematology Am Soc Hematol Educ Program; 2005; ():445-51. PubMed ID: 16304418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacology of selective COX-2 inhibitors.
    Capone ML; Tacconelli S; Sciulli MG; Patrignani P
    Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):49-58. PubMed ID: 14552704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computer aided drug design approaches to develop cyclooxygenase based novel anti-inflammatory and anti-cancer drugs.
    Reddy RN; Mutyala R; Aparoy P; Reddanna P; Reddy MR
    Curr Pharm Des; 2007; 13(34):3505-17. PubMed ID: 18220787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.